Related references
Note: Only part of the references are listed.Expanding Nilotinib Access in Clinical Trials (ENACT) An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphi Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase
Franck E. Nicolini et al.
CANCER (2012)
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
Elias Jabbour et al.
BLOOD (2011)
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
Franck Emmanuel Nicolini et al.
BLOOD (2011)
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria
Sally Arai et al.
BLOOD (2011)
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele et al.
BLOOD (2010)
Stem Cell Transplantation for Patients With Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors With BCR-ABL Kinase Domain Mutation T315I
Nikolai Velev et al.
CANCER (2010)
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'
Gianantonio Rosti et al.
LEUKEMIA & LYMPHOMA (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
A. Hochhaus et al.
LEUKEMIA (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: Revised definitions to predict survival
Daniel Weisdorf et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: Long-term follow-up of the first 285 reported to the National Marrow Donor Program
Sergio Giralt et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia:: historical comparison between two phase 3 trials
Lydia Roy et al.
BLOOD (2006)
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
Elias Jabbour et al.
BLOOD (2006)
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation
DJ Weisdorf et al.
BLOOD (2002)
Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy
R Champlin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
